Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated May 2026 · ClinicalTrials.gov

University Hospital, Basel, Switzerland

13 clinical trials · 13 recruiting · OTHER

University Hospital, Basel, Switzerland has 13 clinical trials registered on ClinicalTrials.gov, with 13 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About University Hospital, Basel, Switzerland\'s Trial Portfolio

University Hospital, Basel, Switzerland is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

13 of University Hospital, Basel, Switzerland's 13 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

University Hospital, Basel, Switzerland's research footprint spans postpartum-hypertension-ppht (1 trials), Multiple Sclerosis (1), and Multiple Sclerosis (ms) (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

is the largest single phase in University Hospital, Basel, Switzerland's portfolio at 54% of registered trials. The full phase breakdown appears in the sidebar.

Trials by University Hospital, Basel, Switzerland

RECRUITINGNCT04690660

Swiss Postpartum Hypertension Cohort

This open label, prospective observational, single-center registry is to study short-, intermediate-and long-term course of postpartum hypertension and predictors/risk factors...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 4801 location
Postpartum Hypertension (PPHT)
RECRUITINGNCT02433028

Swiss Multiple Sclerosis Cohort-Study

The Swiss MS Cohort Study (SMSC) is a multicentre cohort study that involves 8 Swiss Multiple Sclerosis centres. The key aims of the SMSC are 1. To maintain a long-term cohort...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 12008 locations
Multiple Sclerosis
RECRUITINGNCT04819737

Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences

This study is to evaluate the sensitivity and intra-/inter-observer agreement of the averaged magnetization inversion recovery acquisitions (AMIRA) in spinal cord (SC) Multiple...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 101 location
Multiple Sclerosis (MS)
RECRUITINGNCT05595954

Impact of Personalised Cardiac Anaesthesia and Cerebral Autoregulation on Neurological Outcomes in Patients Undergoing...

This international, multicentre prospective cohort study will assess whether perioperative duration and magnitude of mean arterial pressure (MAP) outside of an individual's...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 5004 locations
Postoperative DeliriumPostoperative StrokePostoperative Cognitive Dysfunction
RECRUITINGPhase 3NCT05890664

Colchicine After Electrocardioversion for Atrial Fibrillation

The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 4168 locations
Atrial FibrillationCardiac Arrhythmia
RECRUITINGNCT06927791

MAchine Learning to Boost the Early Diagnosis of Acute Cardiovascular Conditions

The research project aims to develop clinical decision support tools integrating established diagnostic variables and machine learning (ML) models for rapid diagnosis of acute...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 2000001 location
Acute Cardiovascular DiseaseST-segment Elevation Myocardial Infarction (STEMI)NSTEMI - Non-ST Segment Elevation MI
RECRUITINGNCT05127980

Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection

The aim of this study is to assess the occurrence of antibodies cross-reacting with autoantigens that have been detected in the context of SLE in patients with primary EBV...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 801 location
Epstein-Barr Virus (EBV) Infection
RECRUITINGPhase 4NCT04447911

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

Hyponatremia is the most common electrolyte derangement occurring in hospitalized patients. It is usually classified as hypovolemic, euvolemic or hypervolemic. The most common...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 1726 locations
HyponatremiaSIADHLiver Failure+1
RECRUITINGPhase 4NCT03153527

Taper Or Abrupt Steroid Stop: TOASSTtrial

This study is an Investigator-initiated, placebo-controlled, multicenter noninferiority trial, comparing rapid termination of systemic glucocorticoid treatment with a tapering...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 53016 locations
Inflammatory DisorderAutoimmune
RECRUITINGNCT05017766

NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria

This is an explorative, mono-center study including prospectively collected patient samples from the University Hospital of Basel. It is to investigate antimicrobial resistance...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 80001 location
Antimicrobial Resistance (AMR)
RECRUITINGPhase 2NCT05655091

Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment...

This prospective randomized, controlled interventional pilot trial, aims to compare the achievement of the optimal target concentration with continuously administered...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 361 location
Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)
RECRUITINGPhase 4NCT04095572

Alternative Prophylaxis in Female Recurrent Urinary Tract Infections

Urological pathogens are effected by rising antimicrobial resistance rates due to the frequent use of antimicrobials for treatment and prophylaxis. Intravesical instillation with...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 502 locations
Urinary Tract InfectionsUrinary Tract Infection (UTI)
RECRUITINGNCT01485575

Mechanical Properties of the Internal Limiting Membrane and Intraoperative Utility of Brilliant Blue g (Bbg) and...

Intravitreal dyes are intended to make the surgical extraction of the Internal limiting membrane (ILM) safer and more complete. However, the search for an adequate vitaly dye is...

Sponsor: University Hospital, Basel, SwitzerlandEnrolling: 503 locations
Macular Edema

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does University Hospital, Basel, Switzerland have on ClinicalTrials.gov?

University Hospital, Basel, Switzerland has 13 clinical trials registered on the federal ClinicalTrials.gov registry, of which 13 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does University Hospital, Basel, Switzerland study?

University Hospital, Basel, Switzerland's registered trials cover 20 conditions on ClinicalTrials.gov, led by postpartum-hypertension-ppht (1 trial), Multiple Sclerosis (1 trial), Multiple Sclerosis (ms) (1 trial), postoperative-delirium (1 trial), postoperative-stroke (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a University Hospital, Basel, Switzerland clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · 13 trials tracked for University Hospital, Basel, Switzerland.

The this entity record above pulls directly from the NIH ClinicalTrials.gov registry. What follows is the per-entity context — how this entity sits in the broader U.S. clinical trials and research registries distribution and which underlying factors drive the headline numbers.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within active and historical clinical trials with similar size, similar exposure, or similar geography — not the national-level summary alone.